The Treatment of Tuberculosis by Means of the Immune Substances (I. K.) Therapy

The Treatment of Tuberculosis by Means of the Immune Substances (I. K.) Therapy
Author :
Publisher :
Total Pages : 234
Release :
ISBN-10 : CHI:087074349
ISBN-13 :
Rating : 4/5 (49 Downloads)

Book Synopsis The Treatment of Tuberculosis by Means of the Immune Substances (I. K.) Therapy by : Walter H. Fearis

Download or read book The Treatment of Tuberculosis by Means of the Immune Substances (I. K.) Therapy written by Walter H. Fearis and published by . This book was released on 1912 with total page 234 pages. Available in PDF, EPUB and Kindle. Book excerpt:


The Treatment of Tuberculosis by Means of the Immune Substances (I. K.) Therapy Related Books

The Treatment of Tuberculosis by Means of the Immune Substances (I. K.) Therapy
Language: en
Pages: 234
Authors: Walter H. Fearis
Categories: Immunotherapy
Type: BOOK - Published: 1912 - Publisher:

DOWNLOAD EBOOK

Disease Control Priorities, Third Edition (Volume 6)
Language: en
Pages: 506
Authors: King K. Holmes
Categories: Medical
Type: BOOK - Published: 2017-11-06 - Publisher: World Bank Publications

DOWNLOAD EBOOK

Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimic
I. K. therapy (Immunkorper, immune substances) in pulmonary tuberculosis
Language: en
Pages: 102
Authors: William Barr
Categories:
Type: BOOK - Published: 1916 - Publisher:

DOWNLOAD EBOOK

I. K. Therapy (immunkörper, Immune Substances) in Pulmonary Tuberculosis
Language: en
Pages: 82
Authors: William Barr
Categories: Tuberculosis
Type: BOOK - Published: 1916 - Publisher:

DOWNLOAD EBOOK

WHO consolidated guidelines on tuberculosis. Module 4
Language: en
Pages: 72
Authors: World Health Organization
Categories: Medical
Type: BOOK - Published: 2022-04-30 - Publisher: World Health Organization

DOWNLOAD EBOOK

Between 2011 and 2019, WHO has developed and issued evidence-based policy recommendations on the treatment and care of patients with DR-TB. These policy recomme